Effect of patient navigation and financial incentives on smoking cessation among primary care patients at an urban safety-net hospital: A randomized clinical trial

JAMA Internal Medicine

Volumn 177, Issue 12, 2017, Pages 1798-1807

  Lasser, Karen E ^a,b,c   Quintiliani, Lisa M ^a,b   Truong, Ve ^c   Xuan, Ziming ^b   Murillo, Jennifer ^c   Jean, Cheryl ^d   Pbert, Lori ^e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

^d Bridge Over Troubled Waters   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ADULT; AGED; ARTICLE; BLACK PERSON; CLINICAL EVALUATION; CONTROLLED STUDY; FAMILY MEDICINE; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH PROMOTION; HISPANIC; HOUSEHOLD INCOME; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNIST; MAJOR CLINICAL STUDY; MALE; MASSACHUSETTS; MIDDLE AGED; NICOTINE REPLACEMENT THERAPY; ODDS RATIO; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE MEMORY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SAFETY NET HOSPITAL; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; URBAN AREA; YOUNG ADULT; HOSPITAL; INTERVIEW; MOTIVATION; PRIMARY HEALTH CARE; PROCEDURES; PROSPECTIVE STUDY; REWARD; TREATMENT OUTCOME;

BOSTON; FEMALE; HOSPITALS, URBAN; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; MOTIVATION; PATIENT NAVIGATION; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; REWARD; SAFETY-NET PROVIDERS; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 85038130182     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.4372     Document Type: Article

References (41)

1. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current cigarette smoking among adults - United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65(44):1205-1211.
2. Chin MH, Walters AE, Cook SC, Huang ES. Interventions to reduce racial and ethnic disparities in health care. Med Care Res Rev. 2007;64(5) (suppl):7S-28S.
3. Volpp KG, Troxel AB, Pauly MV, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med. 2009;360(7): 699-709.
4. Higgins ST, Washio Y, Heil SH, et al. Financial incentives for smoking cessation among pregnant and newly postpartum women. Prev Med. 2012;55 (40)(suppl):S33-S40.
5. Businelle MS, Kendzor DE, Kesh A, et al. Small financial incentives increase smoking cessation in homeless smokers: a pilot study. Addict Behav. 2014;39(3):717-720.
6. Kendzor DE, Businelle MS, Poonawalla IB, et al. Financial incentives for abstinence among socioeconomically disadvantaged individuals in smoking cessation treatment. Am J Public Health. 2015;105(6):1198-1205.
7. Etter JF, Schmid F. Effects of large financial incentives for long-term smoking cessation: a randomized trial. J Am Coll Cardiol. 2016;68(8): 777-785.
8. Lasser KE, Kenst KS, Quintiliani LM, et al. Patient navigation to promote smoking cessation among low-income primary care patients: a pilot randomized controlled trial. J Ethn Subst Abuse. 2013;12(4):374-390.
9. Levinson AH, Valverde P, Garrett K, et al. Community-based navigators for tobacco cessation treatment: a proof-of-concept pilot study among low-income smokers. BMC Public Health. 2015;15:627.
10. Quintiliani LM, Russinova ZL, Bloch PP, et al. Patient navigation and financial incentives to promote smoking cessation in an underserved primary care population: A randomized controlled trial protocol. Contemp Clin Trials. 2015;45(Pt B): 449-457.
11. Massachusetts Health Promotion Clearinghouse. You Can Quit Smoking. Boston, MA: Massachusetts Department of Public Health; 2010.
12. Sorensen G, Barbeau E, Hunt MK, Emmons K. Reducing social disparities in tobacco use: a social-contextual model for reducing tobacco use among blue-collar workers. Am J Public Health. 2004;94(2):230-239.
13. Emmons KM, Stoddard AM, Fletcher R, et al. Cancer prevention among working class, multiethnic adults: results of the healthy directions-health centers study. Am J Public Health. 2005;95(7):1200-1205.
14. Staddon JE, Cerutti DT. Operant conditioning. Annu Rev Psychol. 2003;54:115-144.
15. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane database of systematic reviews (Online). 2010(1): CD006936. http://onlinelibrary.wiley.com/doi/10 .1002/14651858.CD006936.pub3/pdf. Accessed August 31, 2017. doi: 10.1002/14651858.CD006936.pub3
16. Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial. Arch Intern Med. 2011;171(10):906-912.
17. De Groff A, Schroy PC III, Morrissey KG, et al. Patient navigation for colonoscopy completion: results of an RCT.Am J Prev Med. 2017;53(3):363-372.
18. Salimetrics. High Sensitivity Salivary Cotinine Quantitative Enzyme Immunoassay Kit. 2015. https://www.salimetrics.com/assets/documents/1-2112n.pdf. Accessed July 25, 2017.
19. ARUP Laboratories. Nicotine and Metabolites, Urine, Quantitative. 2017; http://ltd.aruplab.com /Tests/Pub/0092356. Accessed July 25, 2017.
20. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25.
21. Jacob P III, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1668-1673.
22. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
23. Diclemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol. 1991;59 (2):295-304.
24. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385-396.
25. Matheny AP, Wachs TD, Ludwig JL, Phillips K. Bringing order out of chaos: psychometric characteristics of the confusion, hubbub, and order scale. J Appl Dev Psychol. 1995;16(3):429-444.
26. Kanner AD, Coyne JC, Schaefer C, Lazarus RS. Comparison of two modes of stress measurement: daily hassles and uplifts versus major life events. J Behav Med. 1981;4(1):1-39.
27. Donatelle RJ, Prows SL, Champeau D, Hudson D. Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: significant other supporter (SOS) program. Tob Control. 2000;9(suppl 3):III67-III69.
28. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6(suppl 2):S57-S62.
29. Caponnetto P, Polosa R. Common predictors of smoking cessation in clinical practice. Respir Med. 2008;102(8):1182-1192.
30. Haas JS, Linder JA, Park ER, et al. Proactive tobacco cessation outreach to smokers of low socioeconomic status: a randomized clinical trial. JAMA Intern Med. 2015;175(2):218-226.
31. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078-15083.
32. Charlot M, Santana MC, Chen CA, et al. Impact of patient and navigator race and language concordance on care after cancer screening abnormalities. Cancer. 2015;121(9):1477-1483.
33. Shiffman S, Dunbar MS, Benowitz NL. A comparison of nicotine biomarkers and smoking patterns in daily and nondaily smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1264-1272.
34. Lerman C, Schnoll RA, Hawk LWJr, et al. A randomized placebo-controlled trial to test a genetically-informed biomarker for personalizing treatment for tobacco dependence. Lancet Respir Med. 2015;3(2):131.
35. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329.
36. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109(9):1414-1425.
37. Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population study. Addiction. 2014;109(3):491-499.
38. Ryan KK, Garrett-Mayer E, Alberg AJ, Cartmell KB, Carpenter MJ. Predictors of cessation pharmacotherapy use among black and non-Hispanic white smokers. Nicotine Tob Res. 2011;13(8):646-652.
39. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-2520.
40. Carroll KM. Lost in translation?Moving contingency management and cognitive behavioral therapy into clinical practice. Ann N Y Acad Sci. 2014;1327:94-111.
41. Hartzler B, Lash SJ, Roll JM. Contingency management in substance abuse treatment: a structured review of the evidence for its transportability. Drug Alcohol Depend. 2012;122 (1-2):1-10.